More importantly, with reference to the above-mentioned IMpower150 study, a protocol amendment was added to its original design in order to include EGFR+/ALK+ NSCLC-affected patients; remarkably, in that subgroup of patients as well, results managed to be consistent with those of the intention-to-treat population. This evidence concerns the gene EGFR and non-small cell lung carcinoma.